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THE PROMISING VIRAL THREAT TO
BACTERIAL RESISTANCE: THE UNCERTAIN
PATENTABILITY OF PHAGE THERAPEUTICS
AND THE NECESSITY OF ALTERNATIVE
INCENTIVES
KELLY TODD†
ABSTRACT
Bacteriophages, or “phages,” are a category of highly adept and
adaptable viruses that can infect and kill bacteria. With concerns over
the burgeoning antibiotic-resistance crisis looming in recent years,
scientists and policymakers have expressed a growing interest in
developing novel treatments for bacterial infections that utilize
bacteriophages. Because of the great expense associated with bringing
a new drug to market, patents are usually considered the gold standard
for incentivizing research and development in the pharmaceutical field.
Absent such strong protection for a developer’s front end investment,
pharmaceutical development remains financially risky and
unattractive. Unfortunately, recent Supreme Court jurisprudence
analyzing patentable subject matter under 35 U.S.C. § 101 has cast
doubt on whether phage therapeutics would be eligible for strong
patent protection. In order for the promise of phage therapeutics to
become a reality, alternative protections or incentives are likely
necessary. Such a framework would likely include trade secrecy,
regulatory exclusivities, research support, alternative payment models,
or some combination thereof.
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INTRODUCTION
In 2017, headlines across the country praised a miraculous sewer
sludge that brought a man back from the brink of death when all else
failed.1 Many months before, sixty-nine-year-old Tom Patterson had
developed a bacterial infection caused by an often deadly, multidrugresistant strain of Acinetobacter baumannii.2 He was admitted to the
hospital with intense abdominal pain and a fever, where he began
projectile vomiting black bile “like something out of ‘The Exorcist.’”3
After a last resort combination of potent, high-risk antibiotics failed,
Mr. Patterson’s condition worsened, and he slipped into a coma.4
Although told to prepare for the worst, Mr. Patterson’s wife, infectious
disease epidemiologist Dr. Steffanie Strathdee, refused to give up; she
began researching alternative treatments.5 Dr. Strathdee found
promising reports of a type of virus known as a bacteriophage
(“phage”) that can infect and kill bacteria, thereby curing antibioticresistant infections.6 She began contacting countless researchers and
labs with the hope of finding a phage that could target A. baumannii.7
Researchers at Texas A&M University and the U.S. Naval Research
Laboratory in Maryland responded, identifying a few promising phage
candidates that had been isolated from samples taken from a local
sewage plant, as well as some that were stored in existing phage
libraries and labs.8 Dr. Strathdee secured emergency FDA approval to
use the phages, and Mr. Patterson was injected with two individualized

1. Azeen Ghorayshi, Her Husband Was Dying From a Superbug. She Turned
to
Sewer
Viruses
Collected
by
the
Navy,
BUZZFEED
(May
6,
2017),
https://www.buzzfeed.com/azeenghorayshi/navy-phage-viruses-for-antibiotics-crisis?utm_term
=.dh0aywqDM#.vq8BbMY4a [https://perma.cc/F5X2-PZLS] (detailing how a bacteriophage
found in sewage helped cure a man’s life-threatening bacterial infection); Lauren Weber, Sewage
Saved This Man’s Life. Someday It Could Save Yours, HUFFINGTON POST (May 11, 2017),
https://www.huffingtonpost.com/entry/antibiotic-resistant-superbugs-phage-therapy_us_
5913414de4b05e1ca203f7d4 [https://perma.cc/N8NV-DDTB] (same).
2. Scott LaFee & Heather Buschman, Novel Phage Therapy Saves Patient with MultidrugResistant Bacterial Infection, UC SAN DIEGO HEALTH NEWSROOM (Apr. 25, 2017),
https://health.ucsd.edu/news/releases/Pages/2017-04-25-novel-phage-therapy-saves-patient-withmultidrug-resistant-bacterial-infection.aspx [https://perma.cc/AH2E-7EEP].
3. Weber, supra note 1.
4. LaFee & Buschman, supra note 2.
5. Weber, supra note 1.
6. Id.
7. Id.
8. Id.
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phage cocktails.9 After being in a coma for two months, he woke up
three days after the phages were administered.10
Mr. Patterson’s experience illustrates the urgency of the bacterialresistance crisis. With antibiotic resistance becoming an increasingly
lethal and prevalent threat to global public health,11 innovative
antimicrobial products that are capable of treating these dangerous
infections are more important now than ever before. Phages have
demonstrated their efficacy as highly targeted, potent, and adaptable
killers of antibiotic-resistant bacteria. These viruses depend on their
ability to infect bacteria in order to proliferate, and as such have
evolved diverse mechanisms for breaking through bacterial defenses.12
However, they remain relatively harmless to humans, leading
researchers in recent years to identify phage therapeutics as a possible
panacea for the antibiotic-resistance crisis.13 However, this solution
depends on the development of viable phage products, an area that has
seen little investment by biotechnology and pharmaceutical
companies, regardless of its medical promise.14 This lack of innovation
is likely due in large part to the dubious patentability of phages and
phage therapies following the Supreme Court’s decision in Association
for Molecular Pathology v. Myriad Genetics, Inc.,15 which held that
naturally occurring products are not patent-eligible subject matter.16
This Note is the first to closely analyze the patentability of phage
therapies, to discuss the impact of uncertain patentability on
innovation in the phage therapeutics field, and to suggest possible
nonpatent alternatives.

9. LaFee & Buschman, supra note 2.
10. Id.
11. See C. Lee Ventola, The Antibiotic Resistance Crisis, Part 1: Causes and Threats, 40
PHARMACY & THERAPEUTICS 277, 283 (2015) (“Rapidly emerging resistant bacteria threaten the
extraordinary health benefits that have been achieved with antibiotics.” (citation omitted)).
12. Derek M. Lin, Britt Koskella & Henry C. Lin, Phage Therapy: An Alternative to
Antibiotics in the Age of Multi-Drug Resistance, 8 WORLD J. GASTROINTESTINAL
PHARMACOLOGY & THERAPEUTICS 162, 164 (2017), https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC5547374 [https://perma.cc/AAZ4-KAWB] (“Bacteria have evolved numerous
mechanisms to resist infection by lytic phages, and phages have an equally impressive diversity of
mechanisms for breaking this resistance.”).
13. Sara Reardon, Modified Viruses Deliver Death to Antibiotic-Resistant Bacteria, NATURE:
NEWS (June 21, 2017), https://www.nature.com/news/modified-viruses-deliver-death-toantibiotic-resistant-bacteria-1.22173 [https://perma.cc/4NCQ-5JEA].
14. See id. (explaining that the “development of phage therapy has been slow”).
15. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013).
16. Id. at 580.
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This Note argues that to bring about the promise of phage
therapies for the treatment of antibiotic-resistant infections, the
traditional patent-centric model for stimulating drug innovation is
insufficient. Alternative protections or incentives, such as trade
secrecy, regulatory exclusivities, research support, alternative payment
models, or some combination thereof, are likely necessary to spur
phage therapy innovation. Part I explains the development of
antibiotic resistance in bacteria and the growing threat it poses to
global health. Part II discusses the unique characteristics of phages and
the benefits and challenges of creating phage-based treatments. Part
III analyzes the murkiness of recent patent-eligibility jurisprudence
and the weak protection it offers for phage therapies. Finally, Part IV
goes on to address the availability of and need for alternative
protections and incentives that stimulate phage therapy innovation,
including trade secrecy, regulatory exclusivities, governmental
research support and funding, and alternative payment models.
I.

THE GLOBAL ANTIBIOTIC RESISTANCE CRISIS

Like war, religion, and technology, humanity has been
inextricably intertwined with, and shaped by, bacterial disease. Though
modern antibiotics have provided the human race with great relief
from bacterial onslaught, these simple microorganisms have recently
begun developing ways to slip through the chinks in our antibiotic
armor.
A. Bacterial Diseases and the Discovery of Penicillin
Many highly dangerous infectious diseases are caused by
bacteria—a group of microscopic, unicellular prokaryotes that are
defined by their lack of a membrane-bound nucleus and other
specialized organelles that are found in plant and animal cells.17
Bacteria’s small size and flexible metabolic capabilities promote fast
replication and adaptability, allowing these organisms to rapidly
establish a presence in a wide variety of environmental conditions.18
17. Kara Rogers & Robert J. Kadner, Bacteria, ENCYCLOPEDIA BRITANNICA,
https://www.britannica.com/science/bacteria [https://perma.cc/XV2K-4TK8].
18. See, e.g., Robin Andrews, Living in Hell: The Possibility of Life Inside a Volcano, FORBES
(Apr. 15, 2017), https://www.forbes.com/sites/robinandrews/2017/04/15/living-in-hell-thepossibility-of-life-inside-a-volcano/#56725cc51c1d [https://perma.cc/VD7E-EQF4] (noting that
bacterial life is capable of surviving even in “Yellowstone’s superheated, anoxic, acidic hot
springs”); Olivia U. Mason et al., First Investigation of the Microbiology of the Deepest Layer of
Ocean Crust, PLOS ONE, Nov. 2010, http://journals.plos.org/plosone/article?id=10.1371/
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Their adaptability and symbiotic coevolution with life and the
environment has aided the proliferation of the estimated five million
trillion trillion bacteria existing today.19 According to Andrew H.
Knoll, professor of biology at Harvard University, “[w]e definitely live
in a bacterial world.”20
While most bacterial strains have either a neutral or beneficial
impact on humans, less than one percent are pathogenic.21 Bacterial
infections cause an array of symptoms and can result in death.22 Many
profound episodes of human loss throughout history can be attributed
to bacterial infections. One of the most infamous catastrophes, the
Black Death of 1347–1351, was caused by the bacterium Yersinia pestis
and resulted in the death of an estimated 30–50 percent of the
European population, and up to 100 million people worldwide.23
During humanity’s earlier days, similar epidemics of leprosy, plague,
syphilis, cholera, and typhoid fever were the norm,24 profoundly
impacting the development of the world’s habits, commerce, and
culture.25
A monumental turning point came in 1928, when an accidentally
contaminated petri dish led to the discovery of penicillin.26 By 1942,
penicillin was deployed to save the life of a young woman dying of

journal.pone.0015399 [https://perma.cc/UV3B-KM7D] (describing the bacterial communities
found in the deepest layer of the oceanic crust); Arie Nissenbaum, The Microbiology and
Biogeochemistry of the Dead Sea, 2 MICROBIAL ECOLOGY 139 (1975) (discussing bacterial
cultures found in the hypersaline Dead Sea).
19. Planet Bacteria, BBC NEWS (Aug. 25, 1998), http://news.bbc.co.uk/2/hi/
science/nature/158203.stm [https://perma.cc/H5LY-BZ4V].
20. NOVA, How Did Life Begin?, PBS (July 1, 2004), http://www.pbs.org/wgbh/
nova/evolution/how-did-life-begin.html [https://perma.cc/R8EM-CVUZ].
21. Bacterial
Infections,
PUBMED
HEALTH,
https://www.ncbi.nlm.nih.gov/
pubmedhealth/PMHT0024516 [https://perma.cc/J4WJ-VQK8].
22. Id.
23. Kirsten I. Bos et al., A Draft Genome of Yersinia Pestis from Victims of the Black Death,
478 NATURE 506, 506 (2011); TEXTBOOK EQUITY, 2 COLLEGE BIOLOGY 602–03 (2014) (ebook).
24. Philip S. Brachman, Editorial, Infectious Diseases – Past, Present, and Future, 32 INT’L J.
EPIDEMIOLOGY 684, 684 (2003).
25. See Maxine Whittaker, How Infectious Diseases Have Shaped Our Culture, Habits and
Language, THE CONVERSATION (July 12, 2017), https://theconversation.com/how-infectiousdiseases-have-shaped-our-culture-habits-and-language-75061
[https://perma.cc/H38Y-E4E6]
(describing how these bacterial diseases “have changed the structure and numbers of people living
in communities”).
26. Tim
Newman,
How
Do
Penicillins
Work?,
MED. NEWS TODAY,
https://www.medicalnewstoday.com/articles/216798.php [https://perma.cc/T5L8-8BJB].
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streptococcal septicemia following a miscarriage.27 The success of the
discovery provoked interest in antibiotic research, which has led to the
development of the over 150 types of antibiotics on the market today.28
Antibiotic drugs have greatly decreased the number of individuals
dying from standalone bacterial diseases, and have vastly improved the
safety of medicine.29 Antibiotics have changed the course of history by
saving what is estimated to be hundreds of millions of lives over the
course of the past century.30 In recognition of their great impact, the
BBC announced in 2017 that antibiotics had been voted “Britain’s
Greatest Invention.”31
B. The Development of Antibiotic Resistance in Bacteria
While current antibiotics have undoubtedly benefitted global
health, there is still room for improvement. Regardless of the
availability and affordability of these drugs, “[b]acterial infection
remains a leading cause of death in both the Western and developing
world.”32 Research on the subject suggests that multiple factors may be
contributing to our inability to reign in infectious diseases. Chief
among these concerns is the waning efficacy of existing antibiotics. As
small, simple organisms with the proven ability to adapt to new
environments and rapidly regenerate, bacteria are able to quickly
generate new populations of stronger, better-suited pathogens when

27. John Curtis, Fulton, Penicillin and Chance, 34 YALE MED. MAGAZINE, no. 1, 1999,
http://ymm.yale.edu/autumn1999/features/capsule/55396
[https://perma.cc/F6PL-E92Y];
Newman, supra note 26.
28. Antibiotics, NEW MED. INFO. & HEALTH INFO., http://drugs.nmihi.com/antibiotics.htm
[https://perma.cc/CTQ2-4TWL].
29. CTRS. FOR DISEASE CONTROL & PREVENTION, ANTIBIOTIC RESISTANCE THREATS IN
THE UNITED STATES, 2013, at 41 (2013), https://www.cdc.gov/drugresistance/threat-report2013/pdf/ar-threats-2013-508.pdf [https://perma.cc/Q2ZG-BHJY] (“Antibiotics were first used to
treat serious infections in the 1940s. Since then, antibiotics have saved millions of lives and
transformed modern medicine.”). Prior to the discovery of penicillin, women were 50 times more
likely to die in childbirth due to infection. Which Invention Won Britain’s Greatest Invention?,
BBC,
http://www.bbc.co.uk/programmes/articles/5QRlT3MhZLnsTjrGswV2FlJ/whichinvention-won-britains-greatest-invention [https://perma.cc/ZGB2-98DX]. Penicillin also greatly
improved the recovery rate of soldiers who incurred traumatic injuries in battle. Id.
30. CTRS. FOR DISEASE CONTROL & PREVENTION, supra note 29, at 41 (“Without
[antibiotics], 200 million of us wouldn’t be here, and that’s a very conservative calculation.”).
31. Id.; Antibiotics Win Greatest British Invention in Live TV Broadcast, U. OXFORD MED.
SCI. DIVISION (June 16, 2017), https://www.medsci.ox.ac.uk/news/antibiotics-win-greatest-britishinvention-in-live-tv-broadcast [https://perma.cc/DVG8-92L3].
32. 77 ADVANCES IN ENZYMOLOGY & RELATED AREAS OF MOLECULAR BIOLOGY xi
(Eric J. Toone ed., John Wiley & Sons, Inc. 2011).
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faced with a threat.33 When that threat is an antibiotic, bacteria may
develop ways to resist that drug.34
Today, strains of antibiotic-resistant bacteria have emerged for
each class of antibiotic; some of these bacteria have shown resistance
to multiple drugs.35 Because resistance to an antibiotic drug within one
class may confer to a bacterium some resistance to other drugs within
the same class, this is particularly troubling.36 Infection by antibioticresistant bacteria greatly limits the number of treatment options that
are available, and the drugs that remain often have decreased efficacy,
making it harder—and sometimes even impossible—to treat the
infection.37 A recent report by the Center for Disease Control
(“CDC”) estimates that at least two million people in the United States
become infected with antibiotic-resistant bacteria each year, with
23,000 dying as a direct result of the infection.38 By 2050, some experts
predict that the annual number of deaths due to antibiotic-resistant
infections will reach ten million if efforts are not made to curtail
bacterial resistance.39
Bacterial resistance to existing antibiotics has been further
exacerbated by a number of factors. First, humans, and their pathogen
hitchhikers, are able to travel faster and farther than ever before; this
modern development has been linked to the proliferation of
uncommon pathogenic infections in unprepared communities.40 As
more pathogens circulate worldwide, the urbanization of modern
33. Newman, supra note 26.
34. Kimberly Buckmon, BARDA Seeks to Launch a Novel Partnership, a Product
Accelerator to Address Antimicrobial Resistance, OFF. ASSISTANT SEC’Y PREPAREDNESS &
RESPONSE: BLOG (Feb. 19, 2016), https://www.phe.gov/ASPRBlog/Lists/Posts/Post.aspx?ID=176
[https://perma.cc/CLQ4-HXEB] (discussing the increase in and deadliness of bacterial infections
that are resistant to existing antibiotics).
35. Id.
36. Antibiotics: An Overview, KHAN ACAD., https://www.khanacademy.org/science/healthand-medicine/current-issues-in-health-and-medicine/antibiotics-and-antibioticresistance/a/antibiotics-an-overview [https://perma.cc/N36K-CURR].
37. Antibiotic Resistance, WHO (Feb. 5, 2018), http://www.who.int/mediacentre/factsheets/
antibiotic-resistance/en [https://perma.cc/U99F-UZ36].
38. Antibiotic/Antimicrobial Resistance, CTRS. DISEASE CONTROL & PREVENTION (last
updated Mar. 29, 2018), https://www.cdc.gov/drugresistance [https://perma.cc/V9U8-HH33].
39. Cassandra Willyard, The Drug-Resistant Bacteria that Pose the Greatest Health Threats,
NATURE: NEWS (Feb. 28, 2017), https://www.nature.com/news/the-drug-resistant-bacteria-thatpose-the-greatest-health-threats-1.21550 [https://perma.cc/U5WT-ZMEC].
40. See A.J. Tatem, D.J. Rogers & S.I. Hay, Global Transport Networks and Infectious
Disease Spread, 62 ADVANCES PARASITOLOGY 293, 295 (2006) (“[T]he global growth of
economic activity, tourism and human migration is leading to ever more cases of the movement
of both disease vectors and the diseases they carry.”).
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societies has created perfect conditions for a bacterial infection to
quickly and rampantly make its way through the dense populace,41
while the warming climate fuels the expansion of vector-borne
diseases.42 Second, poverty, war, weakened health systems, and poor
infrastructure all likely play a strong role in infectious disease
outbreaks.43
As antibiotic-resistant bacteria continue to proliferate, new
treatments are needed to meet this growing threat. However, research
and development (“R&D”) investments by the pharmaceutical
industry into innovative antibiotics have been sorely lacking. Following
the “golden” pipeline of antibiotic development in the 1960s and ‘70s,
the majority of pharmaceutical manufacturers abandoned the field to
pursue more lucrative therapeutics.44 Low-hanging therapies have
already been discovered, and the costs associated with conducting
highly intensive, complex research have risen to astronomical heights.
As a result, by the turn of the twenty-first century, the number of new
antibiotics in development dropped from dozens to just three.45
The World Health Organization (“WHO”) has identified 12
classes of pathogens that are highly resistant and thus in urgent need
of new treatments.46 While a number of domestic and international
41. Ronak B. Patel & Thomas F. Burke, Urbanization – An Emerging Humanitarian
Disaster, 361 NEW ENG. J. MED. 741, 741 (2009).
42. See Nick Watts et al., The 2017 Report of the Lancet Countdown: From 25 Years of
Inaction to a Global Transformation for Public Health, LANCET, Oct. 2017, at 3 (identifying that
“altered climactic conditions are contributing to growing vectorial capacity for the transmission
of dengue fever by Aedes aegypti”).
43. See Waleed Al-Salem, Jennifer R. Herricks & Peter J. Hotez, A Review of Visceral
Leishmaniasis During the Conflict in South Sudan and the Consequences for East African
Countries, 9 PARASITES & VECTORS, Aug. 22, 2016, at 2 (“Visceral leishmaniasis . . . , also known
as kala-azar, is a serious and often fatal neglected tropical disease . . . that is highly correlated with
war, poverty and failed health systems . . . .”); Julia Belluz, Why is Ebola Less Deadly in America
than in Africa?, VOX (Oct. 28, 2014), https://www.vox.com/2014/10/24/7059743/why-is-ebolavirus-outbreak-american-africa-nina-pham [https://perma.cc/GL74-4C5N] (noting that deficient
health care systems have led to higher rates of death from Ebola in Africa than in the United
States).
44. Jose M. Munita & Cesar A. Arias, Mechanisms of Antibiotic Resistance, 4
MICROBIOLOGY SPECTRUM, Apr. 2016, at 25; see also Ventola, supra note 11, at 279 (discussing
that 15 of the 18 largest pharmaceutical companies have completely abandoned the antibiotic
field).
45. Maryn McKenna, We Need Antibiotics. They’re Not Profitable to Make. Who Pays?,
NAT’L GEOGRAPHIC: SCI. & INNOVATION: GERMINATION (May 23, 2015),
http://phenomena.nationalgeographic.com/2015/05/23/oneill-amr-3
[https://perma.cc/LK76DNJW].
46. WHO, PRIORITIZATION OF PATHOGENS TO GUIDE DISCOVERY, RESEARCH AND
DEVELOPMENT OF NEW ANTIBIOTICS FOR DRUG-RESISTANT BACTERIAL INFECTIONS,
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efforts have been made to incentivize pharmaceutical manufacturers
to invest in the field,47 the vast majority of antimicrobials developed in
conjunction with these programs are small, low-risk improvements to
existing therapeutics.48 Only eight were identified by the WHO as
innovative treatments that may actually add value to the current
treatment arsenal.49
II. PHAGES: USING THE NATURAL ENEMY OF BACTERIA IN NEW
TREATMENTS
Increasing bacterial resistance and the urgent need for novel
antimicrobial therapeutics has reignited interest within the scientific
community about phage therapy.50 This Part introduces phages, their
therapeutic possibilities, and some of the challenges phage therapeutic
manufacturers face.
A. What Are Phages?
Phages, the most abundant biological grouping on earth, are a
category of viruses that are able to infect bacteria.51 The term
“bacteriophage” can be literally translated to “bacteria eater,” in
reference to the virus’s bactericidal capabilities.52 Like most viruses,
phages generally consist of a protein coat that surrounds a core

INCLUDING
TUBERCULOSIS
79
(2017),
http://www.who.int/medicines/areas/
rational_use/PPLreport_2017_09_19.pdf?ua=1 [https://perma.cc/T5UE-RAYY]. The WHO’s list
includes and prioritizes bacterial infections based on their mortality, their burden on healthcare
systems and communities, antibiotic-resistance prevalence and trends, their transmissibility, their
preventability, their treatability, and existing antibiotics in the pipeline. Id. at 78. The top-priority
pathogens are strains of Pseudomonas aeruginosa, a common cause of sepsis and pneumonia;
Enterobacteriaceae, a family of bacteria causing urinary tract and bloodstream infections and
pneumonia; and A. baumannii, which is commonly associated with bloodstream infections and
pneumonia. Id. at 41–42.
47. See infra Part IV.
48. Zosia Kmietowicz, Few Novel Antibiotics in the Pipeline, WHO Warns, BRIT. MED. J.
(Sept. 19, 2017), https://www.bmj.com/content/358/bmj.j4339 [https://perma.cc/MV9N-85LJ].
49. Id.
50. See Dwayne R. Roach et al., Synergy Between the Host Immune System and
Bacteriophage is Essential for Successful Phage Therapy Against an Acute Respiratory Pathogen,
22 CELL HOST & MICROBE 38, 38–39 (2017).
51. James MacDonald, Fighting Bacterial Infection with . . . Viruses?, JSTOR: DAILY (Apr.
2, 2018), https://daily.jstor.org/fighting-bacterial-infection-with-viruses/ [https://perma.cc/R57GJX3E].
52. Bacteriophage, NATURE EDUC.: SCITABLE, https://www.nature.com/scitable/definition/
bacteriophage-phage-293 [https://perma.cc/V83Q-5YB6] [hereinafter Bacteriophage, SCITABLE].
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containing viral DNA or RNA.53 While other forms exist, the most
recognizable phage shape houses the viral genetic material in a
spherical, twenty-sided—or icosahedral—protein shell that is
connected by a tube to a set of spider-like legs.54

Figure 1. Bacteriophage Lytic and Lysogenic Cycles.

As seen in Figure 1. Bacteriophage Lytic and Lysogenic Cycles,55
phages infect their hosts by binding to a bacterium’s cell wall,
perforating the wall through enzymatic action, and injecting viral
genetic material into the bacterium.56 A phage’s genetic material then
effectively “hijacks” the host cell and causes it to produce viral
components that assemble into new phages.57 Eventually, the pressure
of the numerous new viruses within the cell cause the infected
bacterium to rupture and die, and the new phages burst forth to
continue the cycle.58 This, notably, is the only method through which

53. Bacteriophage – Bacteriophage Structure, JRANK, http://science.jrank.org/pages/715/
Bacteriophage-Bacteriophage-structure.html [https://perma.cc/K7SG-PEDQ].
54. See id. (“Bacteriophage have different three-dimensional shapes (or morphologies). Teven phages . . . have a head that has a slightly spherical shape called an icosahedron. A tube
connects the head to spider-like supporting legs.”).
55. Janis Doss et al., A Review of Phage Therapy Against Bacterial Pathogens of Aquatic and
Terrestrial Organisms, 9 VIRUSES 50, fig. 2 (2017).
56. Bacteriophage – Bacteriophage Structure, supra note 53.
57. Bacteriophage, SCITABLE, supra note 52.
58. Id. (describing the process of lysis).
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phages can multiply.59 Some phages also undergo lysogenic cycles,
whereby the phage invades a host nonlethally by injecting it with viral
DNA that is then incorporated into the bacterial DNA and passed
down to subsequent bacterial generations.60 Certain conditions can
cause the dormant prophage DNA to reactivate and initiate a lytic
cycle.61
Like the bacteria they infect, phages can flourish in almost any
environment,62 as they are highly adaptable.63 Researchers hypothesize
that the coevolution of bacteria and phages has been crucial in shaping
the microbial communities that are essential to defining life on Earth.64
As bacteria adapt and change, phages quickly respond, keeping
bacterial populations in check.65 This coevolution makes phages highly
specialized to just one or a few strains of bacteria.66 While a certain
phage strain may only be able to infect one strain of bacteria, a single
strain of bacteria may have multiple types of phages that have adapted
to infect it.67 Studies suggest that this relationship has led to a vast
continuum of genetic variation in the phage world.68
Because the continued existence of a specific phage strain is
conditioned on phages of those type finding a proper bacterial host,
phages targeted to infecting specific strains of bacteria are found

59. See Beata Weber-Dabrowska et al., Bacteriophage Procurement for Therapeutic
Purposes, 7 FRONTIERS MICROBIOLOGY, Aug. 12, 2016, at 2 (“Bacteriophages are viruses which
have the ability to multiply only in bacterial cells . . . .”).
60. Bacteriophages, KHAN ACAD., https://www.khanacademy.org/science/biology/biologyof-viruses/virus-biology/a/bacteriophages [https://perma.cc/PDR8-2S28].
61. Id.
62. Howard Hughes Med. Inst., Understanding Genetic Diversity of Bacteriophage,
PHYS.ORG (Apr. 29, 2015), https://phys.org/news/2015-04-genetic-diversity-bacteriophages.html
[https://perma.cc/SC4V-M8U3].
63. Britt Koskella & Michael A. Brockhurst, Bacteria-Phage Coevolution as a Driver of
Ecological and Evolutionary Processes in Microbial Communities, 38 FEMS MICROBIOLOGY
REV. 916, 924 (2014).
64. Id. at 920.
65. Id. at 923.
66. Id. at 925 (discussing the coevolution of phages and bacteria, the variety of phage
genotypes it produces, and suggesting that this genetic mosaicism means there is “some constraint
upon host range even among the most broadly infectious phages”).
67. Julianne H. Grose & Sherwood R. Casjens, Understanding the Enormous Diversity of
Bacteriophages: The Tailed Phages that Infect the Bacterial Family Enterobacteriaceae,
VIROLOGY, Sept. 19, 2014, at 421–22.
68. See Howard Hughes Med. Inst., supra note 62 (“The study compared the genomes of 627
bacteriophages isolated from a single species of bacteria, and found a continuum of genetic
diversity, rather than discrete groups within the population.”).
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wherever that bacterium is.69 For example, phages exist as highly
specified and highly effective killers in lakes, soil, sludge, fecal matter,
and other bacteria-rich environments.70 Human-altered environments,
such as areas with hospital waste and sewage, therefore offer rich
supplies of phages that are capable of infecting bacteria that are
pathogenic in humans.71
B. Developing Therapeutic Interventions that Utilize Phages
After phages were officially discovered in the early twentieth
century, scientists quickly identified their possible therapeutic
potential.72 In 1917, approximately one year after the first phages were
isolated, microbiologist Felix d’Herelle tested a phage cocktail on a
number of patients suffering from severe dysentery.73 All four patients
recovered within 24 hours after receiving a single dose of phages.74 By
the 1940s, several companies had begun developing and producing
phage therapies targeted at bacterial pathogens such as staphylococci,
streptococci, and Escherichia coli.75
Despite some initial success, the efficacy of these early phage
therapeutics remained controversial within the scientific community.76
Around the same time, antibiotics came bursting onto the scene with
the discovery of penicillin.77 Not long afterwards, the Western world

69. See Dipali Pathak, Bacteriophages, Natural Drugs to Combat Superbugs, PHYS.ORG
(Apr.
18,
2017),
https://phys.org/news/2017-04-bacteriophages-natural-drugs-combatsuperbugs.html [https://perma.cc/2W9F-3YSM] (noting that birds and dogs carrying a particular
Escherichia coli bacteria strain also carry the phages specific to that strain).
70. Weber-Dabrowska et al., supra note 59, at 2, 6.
71. Roja Rani Pallavali et al., Isolation and In Vitro Evaluation of Bacteriophages Against
MDR-Bacterial Isolates from Septic Wound Infections, 12 PLOS ONE, July 18, 2017, at 3,
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179245 [https://perma.cc/
475C-EMG7].
72. See Alexander Sulakvelidze, Zemphira Alavidze & J. Glenn Morris, Jr., Bacteriophage
Therapy, 45 ANTIMICROBIAL AGENTS & CHEMOTHERAPY 649, 649–50 (2001) (discussing the
official discovery of phages by Felix d’Herelle and his subsequent use of phages to treat dysentery
in 1919).
73. Zhabiz Golkar, Omar Bagasra & Donald Gene Pace, Bacteriophage Therapy: A Potential
Solution for the Antibiotic Resistance Crisis, 8 J. INFECTION DEVELOPING COUNTRIES 129, 131
(2014).
74. Id.
75. Sulakvelidze et al., supra note 72, at 650.
76. Id.
77. Id.; Newman, supra note 26.
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abandoned its pursuit of effective phage therapeutics in favor of these
easier-to-produce, cheaper, and more consistent drugs.78
1. Creating Phage-Based Therapeutic Products.
With the
potentially catastrophic effects of antibiotic resistance looming in the
near future, physicians’ and researchers’ interests in phage therapy
have been reinvigorated.79 Mr. Patterson’s sensational story is just one
example of the scientific community testing the waters of phage
therapeutics.80 Phage therapies present a number of observed and
theoretical benefits over traditional antibiotics. Unlike antibiotics,
bacterial resistance to phages is not generally a threat; even the
toughest multidrug-resistant bacteria are fully vulnerable to the right
phage.81 If a bacterial strain exposed to phage therapy does develop
some defense mechanism against phage infection, true resistance is
unlikely to develop.82 Unlike the static chemical compounds that make
up antibiotics, phages are living things. As naturally occurring
organisms with many millennia of natural selection ingrained in their
evolutionary past, phages likely have the innate ability to counter
almost any phage-resistant bacterial adaptations.83 This would allow
physicians to alter phage treatments in real time to kill bacteria, should
resistance develop.84
Unlike traditional antibiotics that may target and destroy good or
neutral systemic bacteria, phages are also highly specified to certain
78. Sulakvelidze et al., supra note 72, at 650. Some research on, and therapeutic use of,
phages continued in a number of Eastern European countries and the Soviet Union; this work
has yielded a fair amount of international literature supporting the safety and efficacy of various
phage therapies. Id.
79. See LaFee & Buschman, supra note 2 (describing the possibilities of phage therapy for
multidrug-resistant infections and personalized medicine).
80. See Carl Zimmer, A Virus, Fished Out of a Lake, May Have Saved a Man’s Life – And
Advanced Science, STAT (Dec. 7, 2016), https://www.statnews.com/2016/12/07/virus-bacteriaphage-therapy/ [https://perma.cc/B2UL-EPDF] (describing another successful use of phage
therapy in the United States).
81. See Joanna Urban, Advancing Phage Therapy, AM. SOC’Y MICROBIOLOGY:
MBIOSPHERE (Jan. 17, 2017), https://www.asm.org/index.php/mbiosphere/item/5471-advancingphage-therapy [https://perma.cc/332W-2ZNP] (“Antibiotic-resistant bacteria are usually fully
sensitive to phages, and because phages are so abundant in nature, multiple phages can be used
together or combined with antibiotics to maximize treatment outcomes.”).
82. Golkar et al., supra note 73, at 131. However, that is not to say that a specific strain of
bacteria cannot become fully resistant to a specific phage strain.
83. See id. (“Like bacteria, phages mutate and therefore can evolve to counter phageresistant bacteria.”).
84. See Pathak, supra note 69 (quoting a scientist working with phages: “Should resistance
develop again, we will evolve another phage - right back at them!”).
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hosts, which limits their ability to bind to off-target sites.85 This makes
them particularly safe therapeutics, with low toxicity and a much lower
risk of negative side effects than traditional antibiotics.86 The relatively
benign systemic effects of phages on humans allow physicians to safely
combine multiple phage strains into therapeutic cocktails when it is
unclear which strain will be effective against a certain bacterium, or
when doing so will synergistically increase the strength of the therapy.87
Finally, a particularly salient strength of phage therapeutics is the
mechanism by which they kill bacteria. Because phages destroy
bacterial cells by reproducing within them, the therapeutic agent itself,
the phage, multiplies at the site of the infection, thus concentrating and
strengthening the treatment where it is needed most.88
2. Biotechnology Companies Currently Researching Phage
Therapies. Reinvigorated interest in phage therapy has prompted both
governmental bodies and a few private biotechnology companies to
begin investigating phage therapeutics. In the United States, the
National Institute of Allergy and Infectious Diseases (“NIAID”) has
identified phage therapy as one of seven prongs in its plan to combat
antibiotic resistance, and has awarded grants to a number of
universities studying phage therapies.89 Although no phage
therapeutics are currently approved for use in humans in the United
States, the Food and Drug Administration (“FDA”) announced in
2017 that it will allow compassionate use.90 The European Commission
expressed its approval in 2014 by funding Phagoburn, the first large,
85. Golkar et al., supra note 73, at 131.
86. Weber-Dabrowska et al., supra note 59, at 2.
87. See id. at 3. Studies have recorded synergistic effects when combining multiple phages
that are each effective against the same host. Id.
88. Id. at 2.
89. Sara Reardon, Phage Therapy Gets Revitalized, NATURE: NEWS (June 3, 2014),
https://www.nature.com/news/phage-therapy-gets-revitalized-1.15348
[https://perma.cc/3UL9UJJP]; Press Release, Nat’l Inst. Health, New NIH Awards Will Support Development of
Therapeutic Alternatives to Traditional Antibiotics (Jan. 12, 2016) [hereinafter New NIH
Awards],
https://www.nih.gov/news-events/news-releases/new-nih-awards-will-supportdevelopment-therapeutic-alternatives-traditional-antibiotics [https://perma.cc/Z9P6-4H9B].
90. Julie Odland, Everything Old is New Again: Bacteriophage Therapy, CLARIVATE
ANALYTICS (Dec. 14, 2017), https://clarivate.com/blog/life-sciences-connect/everything-old-newbacteriophage-therapy/ [https://perma.cc/Z433-VXQB]. “Compassionate use” refers to the use of
investigational, non-FDA-approved therapeutic products for treatment purposes; it is generally
only available in serious or life-threatening situations when all available treatment options have
been exhausted. Expanded Access (Sometimes Called Compassionate Use), U.S. FOOD & DRUG
ADMIN., https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionate
Use/default.htm [https://perma.cc/YR3C-MQNU] (last updated June 19, 2018).
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multicenter, multiyear clinical trial testing phage therapies for human
infections.91
Three private sector companies have taken the lead in
investigating phage therapeutics in the United States. While not geared
toward treating bacterial infections, Intralytix has brought to market a
number of FDA-approved phage products that address food safety
issues.92 On February 15, 2018, Intralytix announced that the FDA
cleared Intralytix’s phage treatment for Crohn’s disease for Phase I/II
clinical trials, making it one of the first phage therapies to begin clinical
testing in the United States.93 Another company, AmpliPhi
Biosciences, was on the team that helped treat Tom Patterson.94
AmpliPhi is currently developing multiphage therapeutics aimed at
treating infections caused by Staphylococcus aureus and Pseudomonas
aeruginosa, both of which are on the WHO’s 2017 Priority Pathogens
List.95 Finally, EpiBiome has developed and brought to market a
superior bacterial profiling service,96 and has developed partnerships
with a number of organizations to leverage this technology in
developing highly targeted phage therapeutics.97
While these ongoing efforts suggest a percolating interest in phage
therapeutics, progress and investment in the field remains minimal in
Western countries.
3. Challenges in Developing Phage Therapeutics. The road to
creating phage therapeutics is not smoothly paved, and many

91. Reardon, supra note 89.
92. Frequently
Asked
Questions,
INTRALYTIX,
http://www.intralytix.com/
index.php?page=faq [https://perma.cc/CBC8-D5AP].
93. Intralytix Receives FDA Clearance to Initiate Phase I/IIa Clinical Trials, INTRALYTIX
(Feb. 15, 2018), http://www.intralytix.com/index.php?page=news&id=87 [https://perma.cc/
6WLE-835P].
94. Marlene Cimons, This Man Should Have Died, But Unusual Infusions Saved His Life,
WASH. POST (July 2, 2017), https://www.washingtonpost.com/national/health-science/this-manshould-have-died-but-unusual-infusions-saved-his-life/2017/06/30/503585b6-4aec-11e7-9669250d0b15f83b_story.html?utm_term=.7fa3b6edc736 [https://perma.cc/4SEP-2REJ].
95. Pipeline, AMPLIPHI BIOSCIENCES CORP., http://www.ampliphibio.com/pipeline/
[https://perma.cc/F4GB-KWH6].
96. See Bacterial Profiling: Why Do We Need to Profile Bacteria?, EPIBIOME,
https://www.epibiome.com/products-services/bacterial-profiling/ [https://perma.cc/VQ58-R4A8]
(describing this profiling service as “breakthrough technology that enables the most reliably
accurate biogram results”).
97. Phage
Based
Technologies:
What
Are
Bacteriophages?,
EPIBIOME,
https://www.epibiome.com/products-services/phage-based-technologies/
[https://perma.cc/
AMW2-GLYQ].
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challenges stand in the way of companies developing these products.
As previously mentioned, the adaptability of phages has produced a
great variety of phages in the natural world.98 Sifting through this vast
number of phages to identify a strain capable of targeting a specific
pathogen involves significant time, effort, and collaboration.99 Further
complicating phage screening and selection are the instability of certain
phage strains when in isolated storage, as well as the risk of a strain
having lysogenic capabilities that can transfer genetic information that
dangerously alters bacterial virulence or resistance.100 Phage-based
product developers also face a number of manufacturing challenges
when isolating, culturing, purifying, sterilizing, preparing, and storing
phages.101 Phage purification and sterilization are particularly delicate
tasks. Because phages must be cultured within bacteria, the resulting
products must be thoroughly filtered to remove any remnants of
hazardous bacterial endotoxins.102 The manufacturing expenses for
phage products likely match the high costs seen elsewhere in the
pharmaceutical industry.103
Importantly, phage products are subject to arguably ill-suited
FDA regulation.104 The clinical trials required by the FDA will likely
be complicated by the immediacy with which treatment is often
required for bacterial infections, the degree of specificity required

98. See Mikael Skurnik, Maria Pajunen & Saija Kiljunen, Biotechnological Challenges of
Phage Therapy, 29 BIOTECHNOLOGY LETTERS 995, 1001 (2007) (reporting a high rate of genetic
novelty among phages sequenced as part of a study of the extensive mosaicism of phage genomes);
see also supra Part II.A.
99. About, PHAGE DIRECTORY, https://phage.directory/about [https://perma.cc/Z5M6AQAV].
100. See Hans-W. Ackermann, Denise Tremblay & Sylvain Moineau, Long-Term
Bacteriophage Preservation, WORLD FED’N FOR CULTURE COLLECTIONS NEWSL., Issue no. 38,
Jan. 2004 (noting difficulties in the long-term storage of phages); Franklin L. Nobrega, Ana Rita
Costa, Leon D. Kluskens & Joana Azeredo, Revisiting Phage Therapy: New Applications for Old
Resources, 23 TRENDS MICROBIOLOGY 185, 185–86 (2015) (noting lysogenic capabilities that risk
transferring new genes to bacteria).
101. See Stephen T. Abedon, Sarah J. Kuhl, Bob G. Blasdel & Elizabeth Martin Kutter, Phage
Treatment of Human Infections, 1 BACTERIOPHAGE 66, 74, 81 (2011) (describing some steps of
the phage manufacturing process).
102. Skurnik et al., supra note 98, at 999.
103. See Catherine Loc-Carrillo & Stephen T. Abedon, Pros and Cons of Phage Therapy, 1
BACTERIOPHAGE 111, 113 (2011) (“Generally these costs of phage production, per unit, are not
out of line with the costs of pharmaceutical production while the costs of discovery (isolation) and
characterization can be relatively low.”).
104. Callum J. Cooper, Mohammadali Khan Mirzaei & Anders S. Nilsson, Adapting Drug
Approval Pathways for Bacteriophage-Based Therapeutics, 7 FRONTIERS MICROBIOLOGY, Aug.
2016, at 11.
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when matching a phage product and a bacterial strain, comorbidities,
and the small number of patients that suffer from the most aggressive
antibiotic-resistant bacterial infections.105 Furthermore, one of the
biggest strengths of phage-based products is the potential to create
precision cocktails or to adapt a cocktail to target an adapting
bacterium.106 It remains unclear whether each altered cocktail would
require full FDA approval as a new therapeutic product.107 Acquiring
FDA approval in advance for each individual phage that may be used
in a cocktail would also be prohibitively expensive, as phage libraries
can include thousands of distinct phages.108 While the FDA has
indicated an interest in addressing these regulatory challenges, the
status of the regulatory pathway for phage therapeutics remains
unclear.109
III. THE PATENTABILITY OF PHAGE THERAPIES
It has long been understood that the unique economic
characteristics of the pharmaceutical industry are largely to blame for
the exceedingly high price associated with bringing a new drug to
market.110 Though there is heated debate surrounding the issue, most
scholars estimate the cost of developing a new drug to be between $1.5
and $2.6 billion.111 The two factors that have emerged as particularly
responsible for the high cost of drug development are the expense of
clinical testing and the high risk of product failure.112
To offset R&D costs, patent protection and other regulatory
exclusivities have proven to be highly important for incentivizing

105. Id. at 2.
106. See supra Part II.B.1.
107. Cooper et al., supra note 104, at 6.
108. Id.
109. See AmpliPhi Biosciences Provides Corporate and Strategic Update, BUS. WIRE (Dec. 14,
2017),
https://www.businesswire.com/news/home/20171214006331/en/AmpliPhi-BiosciencesCorporate-Strategic-Update [https://perma.cc/2EZW-TK26] (stating that the FDA has
“expressed a commitment to addressing the unique regulatory challenges that might arise during
product development”).
110. Iain Cockburn & Genia Long, Editorial, The Importance of Patents to Innovation:
Updated Cross-Industry Comparisons with Biopharmaceuticals, 25 EXPERT OPINION ON
THERAPEUTIC PATS. 739, 740 (2015).
111. Rachel E. Sachs, Innovation Law and Policy: Preserving the Future of Personalized
Medicine, 49 U.C. DAVIS L. REV. 1881, 1889 n.28 (2016).
112. Cockburn & Long, supra note 110, at 739.
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pharmaceutical innovation.113 Patents and other types of exclusivity
allow pharmaceutical manufacturers to extract significant value from
their inventions by granting a limited monopoly during which
competition is prohibited and pricing is discretionary.114 Extracting
sufficient profits from a product during this initial period of exclusivity
is highly important to pharmaceutical manufacturers, as an innovator
drug’s share of market sales drops to near nothing as soon as a less
expensive, generic version is introduced.115 This dynamic has caused
patents to become highly valued in the pharmaceutical industry.116
Numerous studies provide empirical support for the importance of
commercial exclusivities in pharmaceuticals; they report that patents
are used more often, that they are more heavily relied on, and that they
are considered more valuable for innovation in the pharmaceutical
industry than in other comparable industries.117 Many statutory
schemes, such as the Drug Price Competition and Restoration Act of
1984, rely heavily on patent rights to encourage drug manufacturers to
take on challenging R&D by providing a means for them to recoup
those costs in the market.118
A. The Problem of Weak Patent Protection for Phage Therapies
Dubious or categorically excluded patent protection for phage
therapies could have highly negative implications for the development
of phage therapeutics. Because of the unique challenges associated
with developing phage-based therapies, the cost associated with
bringing a phage therapy to market is likely to match, if not exceed, the
multibillion-dollar price tag associated with bringing a new smallmolecule drug to market.119 As previously discussed, phages are
numerous, highly variable, highly specialized, and unlikely to traipse
smoothly through the FDA’s existing regulatory pathway.120 Bacteria

113. See id. (explaining that R&D must be funded by profits from successful, on-market
medicines and that typically, once patent protection lapses, generics launch and their share-value
increases).
114. Frederick M. Abbott, Excessive Pharmaceutical Prices and Competition Law: Doctrinal
Development to Protect Public Health, 6 U.C. IRVINE L. REV. 281, 286–87 (2016).
115. Cockburn & Long, supra note 110, at 740. One study suggests that an innovator drug’s
market share drops to about 16 percent within a year of generic entry. Id.
116. Id. at 739.
117. Id. at 740–41.
118. Id.
119. See supra Part II.B.3.
120. See supra Parts II.A, B.3.
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can also mutate quickly, meaning there is a risk of a specific phage
therapy that is invested in today being rendered worthless tomorrow.121
While one of the strengths of phages is that they can evolve to meet
bacterial resistance, the regulatory roadblocks discussed supra in Part
II.B.3 present a challenge for addressing this resistance in real time.
Bringing new treatments for bacterial infections to market
involves an additional set of challenges for developers that are not as
prevalent for developers of drugs targeting other diseases or illnesses.
Bacterial infections lack a strong array of diagnostics that are able to
quickly and cost-effectively identify specific pathogenic infections
against which an antimicrobial can be tested.122 Because bacterial
infections often require immediate treatment, the lack of good
diagnostic options would likely complicate and lengthen the already
extensive clinical trial process by making it more difficult to identify
proper participants and control for confounding factors.123
Antimicrobials are also taken only for short periods of time and
therefore generate a smaller volume of sales than treatments for
chronic conditions.124 Those sales are unlikely to be recoupable
through high prices due to the public perception associating the
historically high prevalence and low costs of antibiotics with low
value.125 Sales of new antibiotics are further inhibited by medical and
public health policies that encourage the sparing use of newer
antibiotics to preserve their novelty in order to delay the development
of resistance.126 Insufficiently protecting the front end investment of
phage product developers may discourage interest, investment, and
innovation in the field.127

121. See Andrej Godány, Gabriela Bukovská, Jarmila Farkašovská & Ivan Mikula, Phage
Therapy: Alternative Approach to Antibiotics, 58 BIOLOGIA 313, 316 (2003) (explaining how
bacterial strains develop phage resistance and outlining five groups of bacterial resistance).
122. GREGORY W. DANIEL ET AL., DUKE-MARGOLIS CTR. HEALTH POL’Y, TRACKING THE
PROGRESS OF ECONOMIC INCENTIVES FOR ANTIMICROBIAL DRUG DEVELOPMENT IN THE U.S.
AND ACROSS THE GLOBE 6 (2016), https://healthpolicy.duke.edu/sites/default/files/atoms/files/
Antimicrobial%20Economic%20Incentives%20Landscape%20Analysisv2.pdf [https://perma.cc/
DPB6-6D2K].
123. Id.
124. Id. at *6–7.
125. See Ventola, supra note 11, at 279 (“Newer antibiotics are generally priced at a maximum
of $1,000 to $3,000 per course compared with cancer chemotherapy that costs tens of thousands
of dollars. The availability, ease of use, and generally low cost of antibiotics has . . . led to a
perception of low value among payers and the public.”).
126. Id. at 279–80.
127. See supra Part II.B.3.
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Patents also play an important role in signaling value to potential
investors.128 Removing that signal may therefore decrease the funding
opportunities available to companies developing phage therapies to
finance their expensive R&D. Intralytix, one of the most active
patentees in phage therapy, has already demonstrated the value of
their existing portfolio by securing a single investment worth over $17
million.129
Failing to properly protect phage therapy patents could have farreaching implications outside of the field as well. Low levels of
innovation may lead to developers abandoning the field as in the 1940s;
even if developers stay in the market, lack of competition may inhibit
competitive innovation and pricing, or may facilitate the development
of natural monopolies that can perpetually charge monopoly prices.
Without the guarantee of patent protection, fewer second-comers will
be incentivized to enter the market, and competitive pricing will falter.
As concerns about healthcare spending in the United States become
increasingly panicked, physicians may be hesitant to prescribe
expensive phage therapies when traditional antibiotics are currently—
and have historically been—so inexpensive.130 Similar concerns could
discourage insurance companies from covering such treatments.
Discouraging the use of alternative antibiotics like phages could have
the unfortunate effect of exacerbating antibiotic resistance.
B. Mayo, Myriad, and the Changing Patent Landscape
The patentability of phage therapeutics has been called into
question by a number of recent cases that have cast doubt on the
patentability of many life sciences products, and have thrown the
industry into chaos.131 In the first of these cases, Mayo Collaborative

128. Hanna Hottenrott, Bronwyn H. Hall & Dirk Czarnitzki, Patents as Quality Signals? The
Implications for Financing Constraints on R&D, 25 J. ECON. INNOVATION & NEW TECH. 197, 199
(2016).
129. Lesaffre Invests in Intralytix, a US Biotechnology Company, PRNEWSWIRE (July 24,
2017),
https://www.prnewswire.com/news-releases/lesaffre-invests-in-intralytix-a-usbiotechnology-company-300493121.html [https://perma.cc/4QUP-73BR].
130. See Carolyn Y. Johnson, The U.S. Spends More on Health Care than Any Other Country.
Here’s What We’re Buying, WASH. POST (Dec. 27, 2016), https://www.washingtonpost.com/
news/wonk/wp/2016/12/27/the-u-s-spends-more-on-health-care-than-any-other-country-hereswhat-were-buying/?utm_term=.4d15fcd5c03e [https://perma.cc/YRR5-S5QL] (discussing the
mounting concerns with high levels of health care spending in the United States).
131. Arti K. Rai & Jacob S. Sherkow, The Changing Life Science Patent Landscape, 34
NATURE BIOTECHNOLOGY 292, 292 (2016).
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Services v. Prometheus Laboratories, Inc.,132 the Supreme Court held
invalid a patent claiming a method of determining the proper dosage
of a thiopurine drug.133 Depending on how a patient metabolizes
thiopurine drugs, the same dose may be too high and risk harmful side
effects in one patient, while being too low, and likely ineffective, in
another.134 The relevant patent addressed this difficulty in dosing by
claiming a method of measuring the concentration of two known
metabolites of thiopurine in a patient’s blood, and comparing them to
specified maximum and minimum threshold values in order to
determine the proper dosage.135
The statute at issue in Mayo, 35 U.S.C. § 101, defines the
parameters of patentable subject matter as including the invention or
discovery of “any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof.”136
However, the Court acknowledged a longstanding exception to § 101
that excludes “laws of nature, natural phenomena, and abstract ideas”
from inclusion as patent-eligible subject matter.137 The Court in Mayo
analyzed whether the patent claims at issue fell under the first
exclusion category as a “law of nature.” Looking first at the correlation
between the concentration of metabolites and the likelihood of overor underdosage, the Court found the relationship to be unpatentable
as a “natural law.”138 The correlation, argued the Court, concerns “the
ways in which thiopurine compounds are metabolized by the body—
entirely natural processes.”139 The Court then considered whether the
patent claims did “significantly more than simply describe these natural
relations,” or whether the application of the law of nature in the
claimed method was sufficiently transformative.140 The Court found
that the claimed application of the law—having a physician “first
administer a thiopurine drug and [then] measure the resulting
metabolite concentrations” to determine proper dosage—constituted
no more than an instruction to use the “well-understood, routine,
conventional activit[ies] already engaged in by the scientific
132.
133.
134.
135.
136.
137.
138.
139.
140.

Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012).
Id. at 77.
Id. at 73.
Id. at 73–74.
35 U.S.C. § 101 (2012).
Mayo, 566 U.S. at 70 (quoting Diamond v. Diehr, 447 U.S. 175, 185 (1981)).
Id. at 77.
Id.
Id.
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community,” by which a physician would normally utilize such a law.141
The Court therefore held that the claimed application lacked a
sufficiently inventive step.142
The life sciences were dealt another blow the next year by the
Supreme Court’s unanimous decision in Association for Molecular
Pathology v. Myriad Genetics, Inc.143 Prior to that litigation, Myriad
identified and patented the sequences of the BRCA1 and BRCA2
genes, in which are found mutations linked to higher risks of breast and
ovarian cancers.144 The challenged patents covered sequences of parts
of the genes’ isolated DNA and “cDNA”—a synthetic type of DNA
that is created in a lab.145 Unlike naturally occurring DNA, cDNA is
manufactured to include only the portions of the targeted genetic
sequence that code for proteins, with the naturally interspersed
noncoding regions removed.146 The Myriad Court analyzed whether
the patent claims fell under the second exclusion category as a “natural
phenomena,” that is, whether they claimed a product of nature.
Beginning its § 101 analysis with the claims covering isolated genetic
DNA, the Court explained that the company “did not create anything”
new by identifying and isolating the BRCA sequences.147 The BRCA
DNA sequence exists as is in nature, and as such was found to be
unpatentable.148 Unlike genomic DNA, however, cDNA is man-made;
the Court explained that cDNA is therefore distinct from DNA
because “something new” is created when a laboratory technician
produces a DNA product with the noncoding regions removed.149 As
such, cDNA was found to be patent-eligible.
The final case that largely reshaped patentability under § 101 was
Alice Corp. v. CLS Bank International,150 which considered the
patentability of a computer program under § 101’s third judicial
exception for “abstract ideas.”151 In Alice, the Supreme Court refined
and solidified its test for patent subject-matter eligibility under § 101

141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.

Id. at 79–80.
Id.
Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013).
Id. at 583.
Id. at 580, 582.
Id. at 582.
Id. at 590–91.
Id.
Id. at 594–95.
Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347 (2014).
Id. at 2354.
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into a two-step framework that has become known as the “Mayo/Alice
test.” According to January 2018 guidance from the U.S. Patent and
Trademark Office (“USPTO”) on patentable subject matter, the
Mayo/Alice test first requires determining whether a patent claim is
within a judicial exception, that is, whether the claim is “directed to a
law of nature, a natural phenomenon (product of nature) or an abstract
idea.” If so, then a court must determine whether the claim is
nevertheless entitled to patent protection because it involves an
inventive concept, that is, whether “the claim recite[s] additional
elements that amount to significantly more than the judicial
exception.”152
Neither the relevant industries nor the lower courts have received
the Mayo/Alice test favorably. Major concerns are percolating in the
life sciences sector over future patent eligibility153 as the U.S. Court of
Appeals for the Federal Circuit struggles to understand the Court’s
broad, abstruse test.154 Applications of the test following Alice have
largely favored ineligibility, with over 90 percent of post-Alice Federal
Circuit decisions on the issue finding patent ineligibility under Mayo,
Myriad, and Alice, as of March 2017.155 In Ariosa Diagnostics, Inc. v.
Sequenom, Inc.,156 the Federal Circuit applied the Mayo/Alice test to
invalidate a patent claiming a method of amplifying and detecting
paternally inherited cell-free fetal DNA located in a sample of a

152. U.S. PAT. & TRADEMARK OFF., MPEP § 2106 (9th ed. Rev. 08.2017, Jan. 2018). While it
was initially thought that Alice might be limited to software patents, the Federal Circuit validated
its applicability to the life sciences by invoking the test in subsequent biotechnology cases.
Douglas Hallward-Driemeier, Federal Circuit Applies Alice to Biotechnology in Striking Down
Myriad Method of Screening Claims, Leaves Door Open for Narrower Method Claims, ROPES &
GRAY: NEWSROOM (Dec. 18, 2014), https://www.ropesgray.com/en/newsroom/alerts/2014/
December/Federal-Circuit-Applies-Alice-to-Biotechnology-in-Striking-Down-Myriad-Methodof-Screening-Claims [https://perma.cc/6VMW-P46W].
153. Robert L. Stoll, New Patent Subject-Matter Eligibility Test Hurts US Competitiveness,
THE HILL (Jan. 27, 2016), http://thehill.com/blogs/pundits-blog/technology/267139-new-patentsubject-matter-eligibility-test-hurts-us [https://perma.cc/EQG3-WT92].
154. See Steven M. Amundson, The Supreme Court’s Decision in Alice Corp. v. CLS Bank
Has Taken a Heavy Toll on Patents for Computer-Related Inventions, LEXOLOGY (Feb. 16, 2016),
https://www.lexology.com/library/detail.aspx?g=300e6862-012d-49dd-bed4-ba8ae4477397
[https://perma.cc/TL5W-BMQT] (“Absent clear guidance from the Supreme Court, lower courts
have at times had difficulty determining what constitutes an abstract idea and what amounts to
an inventive concept.”).
155. David Kappos, Dir., U.S. Pat. & Trademark Off. 2009–2013, Address at the Federal
Circuit Bar Association & the Center for Innovation Policy at Duke Law Symposium: Are Patents
Under Attack? 9 (Apr. 6, 2018) (PowerPoint slides on file with Duke Law Journal).
156. Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015).
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pregnant woman’s circulating blood.157 Though the court agreed that
the discovery “revolutionized prenatal care” by establishing a
noninvasive means of detecting genetic conditions of a fetus,158 the
court found the method was not an inventive application of a law of
nature under the Mayo/Alice test because the methods of fractioning
blood and amplifying and detecting nucleic acid are “routine,
conventional techniques.”159 The Federal Circuit used similar
reasoning in 2016 to invalidate the patent at issue in Genetic
Technologies Ltd. v. Merial L.L.C.,160 which claimed a method of
detecting a coding region of an individual’s DNA by amplifying and
analyzing linked noncoding regions.161
The courts have invalidated a number of other diagnostic and
method of treatment patents in the wake of Mayo, Myriad, and Alice.
Examples include patents claiming a method of treating patients with
inhaled nitric oxide in a way that decreases the risk of pulmonary
edema,162 patents claiming a method for determining whether a
particular type of drug is likely to be effective based on the presence or
absence of certain genetic mutations,163 and patents covering a method
of diagnosing cardiovascular risk by detecting and analyzing the levels
of a specific enzyme in a biological sample.164
Composition of matter claims have also fared poorly under the
Mayo/Alice test. In Natural Alternatives International, Inc. v. Creative
Compounds, L.L.C.,165 the U.S. District Court for the Southern District
of California considered patents claiming a dietary supplement
comprised of the amino acid beta-alanine.166 The court found that the
claims were actually directed to beta-alanine itself, a naturally
occurring phenomenon.167 As such, even isolated in the form of a

157. Id. at 1373–74.
158. Id. at 1379 (quoting Brief of Appellant at 25, Ariosa Diagnostics, Inc. v. Sequenom, Inc.,
788 F.3d 1371 (Fed. Cir. 2015) (Nos. 2014-1139, 2014-1144)).
159. Id. at 1377 (citing 35 U.S.C.A. § 101 (2012)).
160. Genetic Techs. Ltd. v. Merial L.L.C., 818 F.3d 1369 (Fed. Cir. 2016).
161. Id. at 1372.
162. Mallinckrodt Hosp. Prods. IP Ltd. v. Praxair Distribution, Inc., No. 15-170-GMS, 2017
WL 3867649, at *2 (D. Del. Sept. 5, 2017).
163. Esoterix Genetic Labs. LLC v. Qiagen Inc., 133 F. Supp. 3d 349, 351–52 (D. Mass. 2015).
164. Cleveland Clinic Found. v. True Health Diagnostics LLC, 859 F.3d 1352, 1355 (Fed. Cir.
2017).
165. Nat. Alternatives Int’l, Inc. v. Creative Compounds, LLC, Nos. 16-cv-02146-H-AGS, 16cv-02343-H-AGS, 2017 WL 3877808 (S.D. Cal. Sept. 5, 2017).
166. Id. at *5.
167. Id.
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supplement, the claims were directed at a patent-ineligible product of
nature.168 Because placing a natural substance into a dietary
supplement and administering it to an individual to achieve a
therapeutic effect is a conventional activity, the claims also failed under
step two, the inventive concept prong, of the Mayo/Alice test.169
Life sciences companies are not completely without hope,
however. A few months after Merial, the Federal Circuit upheld a
patent in Rapid Litigation Management Ltd. v. CellzDirect, Inc.170 that
claimed a method of producing liver cells that remain viable following
multiple cryopreservations using density gradient fractionation.171 The
court’s decision was based on its finding that the claim was directed not
at the natural law defining liver cells’ ability to survive multiple freezethaw cycles, but rather at a “new and useful laboratory technique for
preserving [liver cells].”172 The court went on to explain that the claim
would succeed under the Mayo/Alice test’s second step regardless
because while the “individual steps of freezing and thawing were well
known,” the process of repeating those steps to preserve liver cells for
multiple cycles was, as a whole, “far from routine and conventional.”173
CellzDirect clarifies that claims that touch upon a natural law are
not necessarily ineligible for patents, and that the judicial exceptions
are limited to “claims that ‘amount to nothing more than observing or
identifying the ineligible concept itself.’”174 For example, in Xlear, Inc.
v. STS Health, L.L.C.,175 the U.S. District Court for the District of Utah
found that a patent claiming a method of cleaning the nasopharynx of
individuals by nasally administering a solution containing xylitol is
patent-eligible subject matter.176 Though xylitol is a product of nature,
168. Id.
169. Id. at *6. Other post-Mayo/Myriad composition patents have been invalidated, including
patents that cover single-stranded DNA primers, In re BRCA– & BRCA2–Based Hereditary
Cancer Test Patent Litig., 774 F.3d 755, 761 (Fed. Cir. 2014), and cloned animals, In re Roslin
Inst. (Edinburgh), 750 F.3d 1333, 1337 (Fed. Cir. 2014).
170. Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc., 827 F.3d 1042 (Fed. Cir. 2016).
171. Id. at 1046.
172. Id. at 1048.
173. Id. at 1051.
174. Bruce M. Wexler, Evan D. Diamond, Edwin Mok & Alexander Plushanski, Federal
Circuit Upholds Patent Eligibility of a Method of Preserving Liver Cells, Giving Guidance on
Applying Section 101’s Exclusion of Natural Laws, PAUL HASTINGS: INSIGHTS (July 7, 2016)
(quoting CellzDirect, 827 F.3d at 1048), https://www.paulhastings.com/publicationsitems/details/?id=b3eee969-2334-6428-811c-ff00004cbded [https://perma.cc/3QB9-JUA3].
175. Xlear, Inc. v. STS Health, LLC, No. 2:14-cv-00806-DN, 2015 U.S. Dist. LEXIS 167707
(D. Utah Dec. 15, 2015).
176. Id. at *15.
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the court held that a claim directed to “a new or novel application of
xylitol” was patentable as an inventive process or method.177
Another Federal Circuit case, Vanda Pharmaceuticals, Inc. v.
West-Ward Pharmaceuticals International Ltd.,178 considered claims
covering a method of treating schizophrenia with iloperidone by testing
for whether a patient has a poor metabolizer genotype and then
administering either a lower or higher dosage based on the results.179
The court determined that the claims were not directed to the natural
law governing the relationship between iloperidone, metabolism, and
the specified health outcome, but to an application of that natural
law.180 According to the court, “the claims here are directed to a
specific method of treatment for specific patients using a specific
compound at specific doses to achieve a specific outcome.”181 The
patent was therefore found valid.182 A few other cases have upheld
patents that are directed to natural laws or products under the second
step of the Mayo/Alice test. One example is a patent that claims a
method of approximating core body temperature based on readings
from a lateral scan of the forehead and ambient temperature.183
Another example is a claim that recites a method of monitoring drug
metabolite levels that involves quantifying the levels in a urine sample
in a way that accounts for the patient’s degree of hydration.184
Those who find recent 35 U.S.C. § 101 jurisprudence murky and
unclear with regards to the life sciences are in good company. Many
critics argue that the Mayo/Alice test and its subsequent applications
have “undermined certainty and protection for worthy inventions” in
a number of ways.185 This uncertainty is exemplified by “conflicting
Federal Circuit subject matter eligibility decisions regarding patents
covering very similar technologies, and patents found to be ineligible
in the US, but eligible in other countries.”186

177. Id. at *12–15.
178. Vanda Pharms., Inc. v. West-Ward Pharms. Int’l Ltd., 887 F.3d 1117 (Fed. Cir. 2018).
179. Id. at 1121.
180. Id. at 1136.
181. Id.
182. Id.
183. Exergen Corp. v. Kaz USA, Inc., 725 F. App’x 959, 961 (Fed. Cir. 2018).
184. Ameritox, Ltd. v. Millennium Health, LLC, 88 F. Supp. 3d 885, 890 (W.D. Wis. 2015).
185. Manny Schecter, Patent Subject Matter Eligibility 101, IPWATCHDOG (May 8, 2018),
https://www.ipwatchdog.com/2018/05/08/patent-subject-matter-eligibility-101/id=96928/ [https://
perma.cc/YRJ5-BXMB].
186. Id.
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C. The Dubious Patentability of Phage Therapies Under the
Mayo/Alice Test
Although antibacterial resistance is becoming a more pressing
concern and interest in phage-based therapeutics continues to grow,
recent jurisprudence concerning patentable subject matter has cast a
long shadow over the field. Phage-based therapeutic products would
likely be patented under § 101 as a “composition of matter” or a “new
and useful process” for treating an infection.187 Should the product be
patented as a composition of matter, phages isolated from nature
would undoubtedly be patent-ineligible under Myriad.188 Like the
isolated DNA sequences in Myriad, naturally occurring phages would
likely be considered a product of nature.189 One could argue that the
isolation, purification, and sterilization of phages that is necessary to
get the viruses into an administrable form would produce iterations of
phages unlike any that exist naturally. However, a similar argument
was rejected in Myriad; though the isolation of a sequence of DNA
creates a nonnaturally occurring compound, the sequence itself was the
subject matter of the claim.190 Should a phage therapy manufacturer
attempt to patent its product by claiming a naturally occurring phage
as a composition of matter, the manner in which the phage is claimed—
that is, as a purified therapeutic—would therefore likely be insufficient
to save the patent under Myriad.
Though naturally occurring phages are very unlikely to be
patentable as compositions of matter, a stronger argument may be
made for the patentability of modified phages.191 Current advances in
synthetic biology have made it possible for researchers to alter the
phenotypic expression of phages.192 Using CRISPR/Cas-9 or other
methods, the viral DNA of a phage can be altered to achieve a number
of ends, such as changing the range of hosts the phage can infect.193
Phage display technology, which allows for the synthetic expression of
different proteins on the surfaces of phages, is another technique of

187. 35 U.S.C. § 101 (2012).
188. Reardon, supra note 89.
189. Id.
190. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 580 (2013).
191. Reardon, supra note 89.
192. Antonia P. Sagona, Aurelija M. Grigonyte, Paul R. MacDonald & Alfonso Jaramillo,
Genetically Modified Bacteriophages, 8 INTEGRATED BIOLOGY 465, 465 (2016).
193. Id. at 465–67.
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synthetically modifying phages.194 Finally, phage genomes can be
modified through directed evolution.195 Patents covering phage
therapeutics that claim a modified phage as a composition of matter
would more closely resemble the synthetic cDNA patents found valid
in Myriad. Regardless, uncertainty in the validity of such patents
remains. A January 2018 article authored by a life sciences patent
expert argues that the wide availability and applicability of CRISPR to
virtually all situations may threaten the patentability of CRISPRderived products in the future.196 Increasing reliance and knowledge
that genetic engineering techniques can be used to achieve diverse
results could cause the resulting patents to fail to be nonobvious as is
required under other provisions of the patent statute.197 Phages
developed through directed evolution may also be of dubious
patentability as compositions of matter. Because directed evolution
uses serial passaging—continuous culturing within a bioreactor—to
guide or amplify a phage’s natural ability to evolve, the actual
modification of the phage is due to naturally occurring evolutionary
processes.198 Evolution is undoubtedly a natural law, and as one court
explained, claims covering a product of nature whose only
inventiveness come from an application of a law of nature are not
sufficiently inventive under Mayo/Alice.199
Method or process patents covering phage therapeutics—as
opposed to composition of matter patents—may fare slightly better
under Mayo/Alice. Even if phage products themselves are products of
nature, methods of producing modified phages may be patent eligible
if they claim more than an application of a law or product of nature
using “well-understood, routine, conventional activit[ies] already
194. Id. at 468.
195. Id. at 467–68.
196. See Jacob S. Sherkow, The CRISPR Patent Landscape: Past, Present, and Future, 1
CRISPR J. 5, 7–8 (2018) (noting that the “reasonable expectation of success in using CRISPR as
a genome-editing tool for any system or cell type” and the obviousness of “using CRISPR to
accomplish these goals” discourage “the patenting of follow-on inventions”).
197. 35 U.S.C. § 103 (2012); see Sherkow, supra note 196, at 7 (“Now that the power of
CRISPR as a genome-editing technology has been elucidated, is any future application of it
nonobvious?”).
198. See Sagona et al., supra note 192, at 467–68 (explaining the process by which phages can
be directed to evolve through “serial passaging” in a bioreactor).
199. See Nat. Alternatives Int’l, Inc. v. Creative Compounds, LLC, No. 16-cv-02343-H-AGS,
2017 WL 3877808, at *6 (S.D. Cal. Sept. 5, 2017) (“[E]mploying a dietary supplement to
administer beta-alanine—a natural phenomenon—to achieve a high level of carnosine synthesis
in a human—applying a natural law—is insufficient to render the claims at issue patent
eligible . . . .”).
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engaged in by the scientific community.”200 However, the use of genetic
engineering, phage display, and directed evolution methodologies are
already common practices for modifying phages, making such method
claims dubious under both § 101 and § 103.201
Arguably the best option for procuring valid phage therapy
patents would be to mimic the construction of patents seen in Xlear as
a novel method of treatment. Like phages, xylitol is a natural
product.202 However, the Xlear patents were valid only insofar as they
claimed the process by which that natural product would be used in the
treatment of a condition for which it had never been used.203 Though
general knowledge of the ability to treat bacterial infections with
phages has existed for decades, an argument could be made that
developing a treatment method that uses a new strain or combination
of phages that has never been used to treat a certain bacterial infection
is an inventive application of a natural product. However, the authority
and persuasive power of Xlear and its reasoning will remain limited
unless affirmed by higher courts.
D. Current Patenting Efforts and Litigation in the Phage Therapy
Field
While the patentability of phage therapeutics remains uncertain,
phage therapy developers continue to apply for patents in the hopes of
acquiring enforceable protection. Intralytix reports protecting its
investment through the use of “a multi-prong [patenting] approach,
which provides broad and strong protection ranging from protecting
specific bacteriophages . . . to [protecting] methods and applications of
those bacteriophages in various settings.”204 Intralytix’s “throw
everything at the wall to see what sticks” patenting strategy sheds light
on the inner workings of the industry as a whole. Many of the patents
relating to phage therapeutics that have been filed, of which there are
relatively few, employ vastly different strategies for protection. These
strategies include claiming methods of treatment in which phages are

200. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 79–80 (2012).
201. See Sagona et al., supra note 192, at 466–68 (discussing the use of genetic engineering,
phage display, and directed evolution methodologies on phages).
202. Xlear, Inc. v. STS Health, L.L.C., No. 2:14-cv-00806-DN, 2015 U.S. Dist. LEXIS 167707,
at *12 (D. Utah Dec. 15, 2015).
203. Id. at *12–15.
204. Patents, INTRALYTIX, http://www.intralytix.com/index.php?page=patents [https://
perma.cc/6NK2-9L8Q].
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administered,205 patenting phage enzymes as opposed to full phages,206
claiming the use of phages in animals,207 and patenting strains of phages
directly.208 While the diversity of these strategies may be a product of
necessity, it is likely that such wide variety, at least to some degree,
reflects an uncertainty among those invested in phage product R&D as
to how best to achieve strong patent protection. Alternatively, these
diverse strategies may reflect that phage patents still hold some value
as signaling mechanisms for investors, regardless of the actual
enforceability of the patents. This shotgun approach to patent claims
may also reflect expectations in the field that the law under Mayo,
Myriad, and Alice will soon be changed, albeit in an unknown
direction.
Very few suits regarding the validity of patents pertaining to
phages have been brought in recent years. Furthermore, most of these
suits involve patents that only tangentially touch on phages,209 and they
analyze validity based on challenges outside of § 101.210 Because no
case has been brought yet that directly addresses the validity of phage
therapy as patentable subject matter, the uncertainty surrounding
phage therapeutics remains. As more players enter the field, the
likelihood of an impending clash between competitors’ patents is ever
increasing.
IV. INCENTIVIZING INVESTMENT IN PHAGE THERAPIES THROUGH
NONPATENT MEANS
Patent protection has generally been “considered the gold
standard for invention protection,” due in large part to the strength,

205. See U.S. Patent No. 9,850,467 (claiming “[a] method for improving the state of health of
patients infected with adenovirus HadV-5, comprising providing [and administering to the
patient] a T4 phage preparation comprising an effective amounts of T4 phage to inhibit the
proliferation of adenovirus HadV-5 by 50%”).
206. See U.S. Patent No. 9,034,322 (claiming compositions “comprising an effective amount
of [certain] isolated lysin polypeptide[s]”).
207. See U.S. Patent No. 9,433,653 (claiming “[a] method of treating or reducing mortality
due to E. coli diarrhoea in a non-human animal subject” that involves the use of “a composition
comprising as the active ingredient an effective concentration of the isolated bacteriophage
EK88P-1”).
208. See U.S. Patent No. 8,440,446 (claiming “[a]n isolated bacteriophage strain specific
against bacteria belonging to the genus Enterococcus”).
209. See, e.g., Regeneron Pharms., Inc. v. Merus B.V., 144 F. Supp. 3d 530, 574–75 (S.D.N.Y.
2015) (considering a phage-derived recombination system).
210. See, e.g., In re Droge, 695 F.3d 1334, 1335–36 (Fed. Cir. 2012) (determining whether a
claim tangentially related to phages was invalid under 35 U.S.C. § 103).
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ease, and breadth with which patents can be enforced.211 A therapeutic
with limited patent protection is thus unlikely to be a financially
attractive investment for manufacturers under normal market
conditions.212 However, phage therapy is not the first important field to
suffer from being underincentivized or underprotected by the existing
patent framework.213 Finding workable alternatives or supplements to
patent protection has proven successful in other fields and has strong
potential in the field of phage therapeutics.
Trade secrecy—one of the most common nonpatent protections
used in the biopharmaceutical industry—is already being employed by
phage therapy developers. While trade secrecy is an easy way to
achieve some protection for phage therapies, this protection is limited.
A strong case can be made for establishing a period of regulatory
exclusivity for phage therapies to supplement trade secrecy, though
such periods are generally granted only for a short time. Although they
do not address the threats posed by competitors, governmentsponsored research funding and collaborations, as well as alternative
payment models for phage therapies could provide additional
incentives in the field by addressing cash flow issues at different points
in the product’s life cycle.
A. Trade Secrecy
Chief among nonpatent protections in the pharmaceutical field is
trade secrecy. A trade secret is confidential information that gives a
business a competitive edge.214 These rights are judicially enforceable
when the secret is not generally known to the public, and derives some
economic benefit from being unknown, and is kept secret through

211. John Artz, Brandon Debus & Franklin Smith, To Disclose or Not to Disclose: Trade
Secrets vs. Patents, LAW360 (Sept. 25, 2017), https://www.law360.com/articles/964200/to-discloseor-not-to-disclose-trade-secrets-vs-patents [https://perma.cc/37GW-BSXH].
212. Alexandra Henein, What Are the Limitations on the Wider Therapeutic Use of Phage?, 3
BACTERIOPHAGE, Apr.–June 2013, 4–5 (2013).
213. For example, discoveries in the field of basic research are generally patent ineligible as
laws or products of nature; these discoveries are nevertheless highly important building blocks
for future innovation. Instead of relying on private patent rights, basic research is incentivized by
an alternative model, whereby public funding is awarded to universities that conduct such
research. See Désirée Schauz, What is Basic Research? Insights from Historical Semantics, 52
MINERVA 273, 318–19 (2014) (detailing the development of “basic research” as a concept so
federal funding could be secured for research that does not produce immediate commercial
benefit).
214. Tara Nealey, Ronald M. Daignault & Yu Cai, Trade Secrets in Life Science and
Pharmaceutical Companies, COLD SPRING HARBOR PERSP. MED., Nov. 2014, 3.
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reasonable efforts.215 Trade secrecy offers protection for information
that may not be eligible for patent protection.216 It also has additional
competitive benefits; unlike patents, trade secrets do not require
disclosure to competitors, and they can be held indefinitely.217 As such,
using trade secrecy to protect investments has become the norm in a
number of life sciences fields where patent protection is insufficient.218
Two fields in which trade secrecy has played an important role in
incentivizing competition and innovation are biologics and genetic
testing. In the biologics space, the complexity and sensitivity of the
product requires the development of highly sophisticated
manufacturing processes.219 However, it can be difficult to protect that
investment through manufacturing process patents, as they can be
difficult to enforce and offer only temporary protection.220 Trade
secrecy has therefore been adopted by many biologics producers to
protect intellectual property relating to manufacturing processes.221
Because trade secrecy extends indefinitely and the details of those
processes are not forced into the public domain, fewer biosimilar
competitors find it financially viable to reverse engineer the complex
processes with enough precision to produce acceptable biosimilars.222
This indefinite pseudomonopoly makes trade secrecy extremely
valuable to biologics manufacturers.223
Trade secrecy could have a number of applications for phage
therapy manufacturers. As is the case with biologics, keeping
production processes as trade secrets could provide a competitive edge
by making it harder for others to reverse engineer similar phage
products.224 Innovative methods of purifying, preparing, amplifying, or

215. Id.
216. W. Nicholson Price II, Making Do in Making Drugs: Innovation Policy and
Pharmaceutical Manufacturing, 55 B.C. L. REV. 491, 533 (2014).
217. Id.
218. Eric Lawrence Levi, Using Data Exclusivity Grants to Incentivize Cumulative Innovation
of Biologics’ Manufacturing Processes, 66 AM. U. L. REV. 911, 947 (2017).
219. Id. at 923.
220. Price, supra note 216, at 533.
221. W. Nicholson Price II & Arti K. Rai, Manufacturing Barriers to Biologics Competition
and Innovation, 101 IOWA L. REV. 1023, 1046 (2016).
222. Id.
223. Id. at 1046–48.
224. Sofie Rombouts, Management of the Bacterial Pathogens Xanthomonas Campestris PV.
Campestris and Pseudomonas Syringae PV. Porri in Cabbage and Leek Production Using Novel
Bacteriophages, at *149 (Feb. 16, 2017) (unpublished Ph.D. dissertation, The Katholieke
Universiteit Leuven).
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storing phages would be protectable as trade secrets. AmpliPhi
Biosciences has already incorporated trade secrecy into its business
model, reporting in its 2018 SEC Annual Report that to “protect [its]
proprietary know-how, which is not patentable, and for inventions for
which patents may be difficult to enforce, [it] currently and will in the
future rely on trade secret protection . . . to protect [its] interests.”225
The significant genetic variability of phages may also lead to the
building of large phage libraries that can be used to create personalized
treatments. Such libraries could possibly be maintained as trade
secrets. However, this trade secrecy would not be boundless.
Knowledge of the strains of phages themselves, of the composition of
a cocktail of phages, and of their efficacy against a certain bacterium
would likely no longer be considered a trade secret once the product is
administered to members of the public. Therefore, while trade secrecy
does provide some value for phage therapy manufacturers, its
protection is likely limited to certain internal processes that would be
difficult to replicate.226
Overreliance on trade secrecy may also have its drawbacks. As
with biologics and biosimilars, maintaining extensive trade secrecy
over phage product manufacturing processes may ratchet up the costs
of follow-on innovation.227 Hiding the discovery of new strains of
phages in private silos may also inhibit the efficiency of basic and
applied research228 by shielding the “building blocks of human
ingenuity” from potential future phage researchers and inventors.229
Furthermore, phages have possible applications outside of human
health in industries ranging from food safety to environmental

https://lirias.kuleuven.be/bitstream/123456789/562531/1/Dissertation+Sofie+Rombouts_final.pdf
[https://perma.cc/XSW4-US9A].
225. AmpliPhi Biosciences Corp., Annual Report (Form 10-K) (Mar. 14, 2018).
226. See generally Jacob S. Sherkow, Protecting Products Versus Platforms, NATURE
BIOTECHNOLOGY: BIOENTREPRENEUR (May 6, 2016), https://www.nature.com/bioent/2016/
160401/pdf/bioe.2016.4.pdf [https://perma.cc/9CET-VUCG] (identifying specific biotechnology
fields that may benefit from trade secrecy because those fields internally use some method or
know-how that would be nearly impossible for an outsider to replicate by reverse engineering the
end product).
227. See Price & Rai, supra note 221, at 1028 (describing the high costs of bringing new
biologics to market due to trade secrecy in their manufacturing processes).
228. “Basic” research refers to research undertaken primarily for the sake of producing new
knowledge, while “applied” research is geared toward more practical outcomes. Peter James
Bentley, Magnus Gulbrandsen & Svein Kyvik, The Relationship Between Basic and Applied
Research in Universities, 70 HIGHER ED. 689, 689–90 (2015).
229. Alice Corp. v. CLS Bank Int’l, 134 S. Ct. 2347, 2354 (2014).
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sanitation to animal health.230 Keeping new strains or related
information secret could have the unfortunate off-target effect of
creating deadweight loss in non-health industries by hiding from
potential noncompetitor inventors the key building blocks for
innovation in their fields.
At bottom, while trade secrecy holds some value for phage
therapy developers, it is lacking in a number of ways. In the absence of
patent protection, additional solutions are likely needed to supplement
trade secrecy in the phage therapeutic field.
B. Regulatory Exclusivities
Another alternative for incentivizing innovation in phage
therapeutics is regulatory exclusivity. A number of different regulatory
exclusivities are currently awarded by the FDA to incentivize
investment by pharmaceutical companies.231 One of the broadest
categories of exclusivity offered by the FDA is for new chemical
entities, which are drugs that contain no active moiety—a molecule or
ion that is responsible for the pharmacological effect of the drug—that
has previously been approved by the FDA.232 Exclusivity granted for a
new chemical entity rewards manufacturers with a five-year period of
data exclusivity, during which time no competitor can be approved to
market a product that relies on the originator’s safety and efficacy
data.233 Relying on an innovator drug’s safety and efficacy data allows
follow-on manufacturers to avoid the significant expenses associated
with full clinical trials so they can bring a cheaper version of the drug
to market through a generic approval pathway established by
Congress.234 When this cheaper route to regulatory approval is not
available, generic manufacturers are unlikely to enter the market and
innovator drugs can maintain their market share. This kind of data
exclusivity, however, may provide little incentive for investing in phage
therapeutics, as no similar generic approval pathway currently exists
for phage products.

230. Platform
Technologies
&
Market
Applicability,
INTRALYTIX,
http://www.intralytix.com/index.php?page=tech [https://perma.cc/P262-J7FL].
231. Patents and Exclusivity, FDA/CDER SBIA CHRON., 2–3 (May 19, 2015),
https://www.fda.gov/downloads/drugs/developmentapprovalprocess/smallbusinessassistance/uc
m447307.pdf [https://perma.cc/N78W-XADA].
232. Id. at 2.
233. Id.
234. Erika Lietzan, The Myths of Data Exclusivity, 20 LEWIS & CLARK L. REV. 91, 93 (2016).
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A more sweeping type of exclusivity is granted by the FDA for
orphan drugs, which treat diseases affecting less than 200,000 people in
the United States or which have no hope of recovering R&D costs.235
Orphan drug exclusivity provides seven years of market exclusivity,
during which time no other application for the same drug for the same
disease can be approved.236 Market exclusivity is therefore broader
than data exclusivity in that it prevents a product from reaching the
market even if it is fully supported by original data.237 This has led some
to describe the market exclusivity granted by the Orphan Drug Act238
as “similar to a patent on a particular use of a drug, [that is] enforced
by FDA.”239 Since orphan drug exclusivity was established, there has
been a marked increase in drug approvals for orphan diseases, and
there has been more interest by manufacturers in the development of
orphan drugs.240
Scholars have suggested that adopting a reward similar to orphan
drug exclusivity would be an appropriate incentive for phage therapy
innovation.241 Similar to orphan drugs, phage therapy products would
be unlikely to recoup their costs due to low sales volume. Phage
therapies are only taken for a short time period, and they are highly
targeted; this means that phage therapies have a small customer base
that would only purchase the drugs in small quantities.242 The principle
of effective antibiotic stewardship, whereby newer and stronger drugs
are prescribed less to fend off antibiotic resistance, would also impair

235. Patents and Exclusivity, supra note 231, at 2.
236. Id.
237. See Lietzan, supra note 234, at 103 (providing proper definitions for market and data
exclusivity).
238. Orphan Drug Act, Pub. L. No. 97-414, 96 Stat. 2049 (1983) (codified as amended in
scattered sections of 21, 26, 35, 42 U.S.C. (2018)).
239. Rebecca S. Eisenberg, Patents and Regulatory Exclusivity, in THE OXFORD HANDBOOK
OF THE ECONOMICS OF THE BIOPHARMACEUTICAL INDUSTRY 167, 184 (Patricia M. Danzon &
Sean Nicholson eds., 2012).
240. Clemens Stockklausner, Anette Lampert, Georg F. Hoffmann & Markus Ries, Novel
Treatments for Rare Cancers: The U.S. Orphan Drug Act is Delivering – A Cross-Sectional
Analysis, 21 ONCOLOGIST 487, 489 (2016). However, it is worth noting that some scholars have
recently questioned whether this increased investment is due mainly to the market exclusivity
period established by the Orphan Drug Act, or whether other parts of the Act, such as the tax
credit it offers for clinical testing costs, may play a bigger role. Ameet Sarpatwari, Reed F. Beall,
Abdurrahman Abdurrob, Mengdong He & Aaron S. Kesselheim, Evaluating the Impact of the
Orphan Drug Act’s Seven-Year Market Exclusivity Period, 37 HEALTH AFFAIRS 732, 736 (2018).
241. ADVANCES IN VIRUS RESEARCH: BACTERIOPHAGES, PART B 79 (Malgorzata Lobocka
& Waclaw T. Szybalski eds., 1st ed. 2012).
242. Henein, supra note 212, at 3.
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phage therapy sales.243 Market exclusivity would help phage therapy
manufacturers recoup their costs by allowing them to extract value
from their products over a nonpatent monopoly period. Because of the
dubious patentability of phage therapeutics, appropriately tailored
market exclusivity could serve well as a stand in for patents for
protecting phage therapy investment.
Congress recognized the value of regulatory exclusivities for
antibacterial innovation in the 2012 Generating Antibiotic Incentives
Now (“GAIN”) Act.244 The GAIN Act makes certain qualified
infectious disease products (“QIDPs”) eligible for fast track and
priority review by the FDA.245 It also extends previously established
exclusivities, including new chemical entity exclusivity and orphan
drug exclusivity, by five years for QIDPs.246 While the GAIN Act is
encouraging, it is still a flawed fit for phage therapies since the
exclusivities extended by the Act are not well tailored to the needs of
the industry. Establishing a unique QIDP market exclusivity period
would more clearly and comprehensively protect phage therapy
investments and serve as a strong complement to trade secrecy.
However, because market exclusivities generally protect products for
a shorter period than patent protection,247 additional incentives may
still be necessary.
C. Governmental Incentives
As the GAIN Act demonstrates, governmental efforts have the
potential to play a pivotal role in incentivizing the development of
phage therapeutics. Indeed, increasing awareness of the promise of
phage therapies within the government and nonprofit sectors has
already prompted a number of such efforts.248
Outside of the FDA, two main players in the field are NIAID and
the Biomedical Advanced Research and Development Authority
(“BARDA”). NIAID’s efforts were initiated by President Obama’s
National Action Plan for Combating Antibiotic-Resistant Bacteria,
243. Id.
244. GAIN Act, Pub. L. No. 112-144, §§ 801–806, 126 Stat. 993, 1077–82 (2012).
245. Id. §§ 802–803.
246. Id. § 801.
247. Patents generally provide protection for an average of 12 years after the product comes
to market, while concurrently running regulatory exclusivities usually expire five to seven years
after the product comes to market. See Patents and Exclusivity, supra note 231, at 2 (noting the
expiration periods for various categories of regulatory exclusivities).
248. Reardon, supra note 89.
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which directed governmental agencies to support research into the use
of “phage and phage-derived lysins to kill specific bacteria,” as well as
other nontraditional antibiotics.249 As part of this initiative, NIAID
awarded over $5 million in funding for 24 research projects, seven of
which involved phages.250 This funding has already proved fruitful; for
example, one NIAID-funded study used phage lysins to develop a
small molecule capable of inhibiting the growth and lethality of
Staphylococcus aureus and Bacillus anthracis.251 While NIAID’s efforts
are mostly focused in the field of basic research, BARDA supports the
advanced development of medical products aimed at addressing public
health threats, including “pandemic influenza, and emerging infectious
diseases.”252 As part of this mission, BARDA helped launch and fund
the Combating Antibiotic Resistant Bacteria Biopharmaceutical
Accelerator, a public-private partnership that provides funding and
support for private biotechnology companies engaged in developing
products that treat antibiotic-resistant bacteria.253
Grant funding is not the only relevant incentive being considered
by the government. In March 2017, the Reinvigorating Antibiotic and
Diagnostic Innovation Act was introduced into Congress.254 Similar to
the Orphan Drug Act, this legislation, which appears to have since died
in committee, would have provided manufacturers up to a 50 percent
tax credit for the expenses associated with clinical testing for a QIDP.255
Another bill, the Promise for Antibiotics and Therapeutics for Health
Act, sought to establish a new approval pathway for antibacterial drugs
aimed at treating serious infections or diseases in limited
populations.256 However, that bill died in Congress.257 Another piece of
legislation, which met a similar fate, attempted to extend Medicare

249. EXEC. OFF. OF THE PRESIDENT, NATIONAL ACTION PLAN FOR COMBATING
ANTIBIOTIC-RESISTANT BACTERIA 44 (2015).
250. New NIH Awards, supra note 89.
251. Research Program Accomplishments, NAT’L INST. OF ALLERGY & INFECTIOUS
DISEASES, https://www.niaid.nih.gov/research/antibacterial-research-program-accomplishments
[https://perma.cc/SHS4-RRRX].
252. U.S. DEP’T HEALTH & HUM. SERVS., BARDA STRATEGIC PLAN 2011-2016, at 5 (2011).
253. CARB-X Injects Up to $48 Million to Accelerate First Powered by CARB-X Portfolio,
B.U. L. NEWS (Mar. 30, 2017), http://www.bu.edu/law/2017/03/30/powered-by-carbx/
[https://perma.cc/4SRW-DH5F].
254. H.R. 1840, 115th Cong. (2017).
255. Id. § 45S(a).
256. S. 185, 114th Cong. (2015).
257. S. 185 (114th): PATH Act, CONGRESS.GOV, https://www.congress.gov/bill/114thcongress/senate-bill/185 [https://perma.cc/E3NN-TEVS].
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coverage for new antibiotic therapies to insulate prescribing decisions
from cost concerns.258
D. Alternative Payment Models
Finally, alternative payment models have recently been theorized
as a novel answer to the issue of underincentivized, low-sales-volume
drugs. Delinkage models suggest establishing a predetermined
financial reward for any developer who brings a new product to
market, thus “delinking” the connection between usage and revenue.
One such model would be to reward developers with tradable vouchers
that extend patent or regulatory exclusivity, which are highly valuable
and can be sold to blockbuster drug manufacturers for hundreds of
millions of dollars. Delinkage was incorporated into the Improving
Access to Affordable Prescription Drugs Act, which was introduced in
Congress in March 2017, although it appears to have since been
unfortunately abandoned.259 This legislation would have offered
monetary prizes from a $2 billion fund for antimicrobial developers
who developed a high-priority drug.260
Other alternative payment models could have the dual benefits in
the field of antimicrobials of encouraging appropriate antibiotic use
and appropriately compensating manufacturers.261 Population-based
payment models compensate developers based on the value of the drug
to society, linking revenue not to sales volume, but to indicators of
value such as the availability of the drug when needed, appropriate use
of the drug by physicians, and the continued effectiveness of the
drug.262 Because population-based payment theories are rooted in the
principle of effective stewardship, under such a model “having a drug
for a low prevalence infection would be highly valuable.”263 The
applicability of such payment models to phage therapeutics is quite
clear. Because of the narrow host range of any one phage-based
product, they will likely never replace traditional, widely used, broad-

258. H.R. 512 - DISARM Act of 2015, CONGRESS.GOV, https://www.congress.gov/bill/114thcongress/house-bill/512 [https://perma.cc/FY2B-9R2C].
259. S. 771, 115th Cong. (2017).
260. Id. § 301.
261. See GREGORY W. DANIEL ET AL., DUKE-MARGOLIS CTR. FOR HEALTH POL’Y, VALUEBASED STRATEGIES FOR ENCOURAGING NEW DEVELOPMENT OF ANTIMICROBIAL DRUGS 12–
13 (2017) (describing several potential models for encouraging antimicrobial development).
262. Id. at 13.
263. Id.
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spectrum antibiotics.264 However, their targeted nature and
adaptability make them an extremely powerful last line of defense
against particularly aggressive pathogens.265 As such, phage therapies
are a prime example of a drug that provides very high value to a small
population.
CONCLUSION
Innovation in the pharmaceutical industry currently relies heavily
on patent protection to incentivize investment by providing strong
monopoly pricing power for new drugs. However, recent § 101
jurisprudence will likely make patenting phage products difficult, if not
entirely impossible. Without strong patent protection, alternative
incentives are likely needed to encourage the level of innovation that
is necessary to address the antibiotic resistance crisis. Trade secrecy
and process patents will likely remain somewhat valuable for
protecting phage product manufacturing processes. However,
establishing an FDA-mandated market exclusivity for phage therapies,
similar to orphan drug exclusivity, would likely be more effective in
creating patent-like monopoly power. Because regulatory exclusivities
generally last for a shorter time than the effective life of a patent,
additional incentives—such as financial subsidies for R&D through the
government or nonprofits, or the decoupling of revenue from sales
volume—will likely be needed for robust innovation in the phage
therapeutics market. With the specter of a catastrophic antibioticresistant bacterial epidemic likely looming in the near future,266 it is
imperative that innovative phage therapies and other nontraditional
antimicrobials are properly incentivized before it is too late.

264. Reardon, supra note 89.
265. Id.
266. See Jonathan Quick, Are We Prepared for the Looming Epidemic Threat?, THE
GUARDIAN (Mar. 18, 2018), https://www.theguardian.com/commentisfree/2018/mar/18/endepidemics-aids-ebola-sars-sunday-essay [https://perma.cc/JHL3-HHKW] (describing the risk of a
new virus causing an epidemic).

